|Systematic (IUPAC) name|
|Pregnancy cat.||B3 (Australia), C (US)|
|Legal status||Schedule 4 (Australia), Rx only (US)|
where a+b:c = 9:1
| (what is this?)
Sevelamer (rINN) (pron.: // or //) is a phosphate binding drug used to treat hyperphosphatemia in patients with chronic kidney disease. When taken with meals, it binds to dietary phosphate and prevents its absorption. It is marketed by Genzyme (now Sanofi-Aventis) under the trade names Renagel (sevelamer hydrochloride) and Renvela (sevelamer carbonate).
Chemistry and pharmacology 
Sevelamer is a copolymer of 2-(chloromethyl)oxirane (epichlorohydrin) and prop-2-en-1-amine. The marketed form sevelamer hydrochloride is a partial hydrochloride salt being present as approximately 40% amine hydrochloride and 60% sevelamer base. The amine groups of sevelamer become partially protonated in the intestine and interact with phosphorus molecules through ionic and hydrogen bonding.
Clinical use 
Sevelamer therapy is contraindicated in hypophosphataemia or bowel obstruction.
Adverse effects 
Other effects 
Sevelamer can significantly reduce serum uric acid. This reduction has no known detrimental effect and several beneficial effects, including reducing hyperuricemia, uric acid nephrolithiasis, and gout.